Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB-201/HB-202 in HPV16-positive cancers
NL-OMON54432Phase 2Withdrawn
- Sponsor
- HOOKIPA Pharma
- Start
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of HB-201, HB-202 and pembrolizumab, sponsored by HOOKIPA Pharma. Planned start Sep 2021; status: withdrawn.
02
Drugs
Beyond the preview
Go deeper on NL-OMON54432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54432.